Pfizer’s gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
The hemophilia A treatment could become the company’s second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains
